Archives

– Next-generation immunotherapy called MyISA® for individual cancer patients

Leiden, The Netherlands, December 7, 2016 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, has joined the recently established Tumor neoantigEn SeLection Alliance (TESLA), a global cancer neoantigen alliance forged by the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute, which was announced on December 1st, 2016. Consisting of 30 of the world’s leading research organizations and corporations, the group’s focus will be on developing better predictive models for identifying neoantigens. The initiative will support tests carried out by its members and the consistent improvement of algorithms to analyze tumor

ISA Pharmaceuticals participates in the newly-launched Tumor neoantigEn SeLection Alliance (TESLA), run by the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI). Read the full press release here:

http://www.parkerici.org/media/2016/parker-institute-for-cancer-immunotherapy-cri-neoantigen-alliance

ISA´s CSO Prof. Cornelis Melief  has written a commentary called “Treating the immune system, not the tumour” for MedNous, October 2016: http://www.mednous.com/sites/default/files/CommentaryCornelisMeliefOct2016.pdf

– Prof. Melief co-chairs Plenary Session 1: Antigens and Vaccines

Leiden, The Netherlands, September 21, 2016 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced that Prof. Cornelis Melief, M.D., and Robert D. Schreiber, Washington University School of Medicine, St. Louis, MO, will jointly chair “Plenary Session 1: Antigens and Vaccines” on September 25, 2016, 8:50 am – 12:00 pm EST at the upcoming CRI-CIMT-EATI-AACR Meeting in New York City.

During the session, Melief will give a presentation titled “Selection of cancer antigens and conditions for success of immunotherapy of

In June 2016,  Kees Melief (CSO of ISA Pharmaceuticals) was named researcher of the week of the Dutch Cancer Society (DCS), a nation-wide organization for cancer-related work in The Netherlands. Read here the interview with him (in Dutch):

https://www.kwf.nl/onderzoek/welk-onderzoek-krijgt-geld/Pages/onderzoeker-van-de-week-Kees-Melief.aspx

Leiden, The Netherlands, June 03, 2016 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the appointment of Bart Bergstein as Chairman of its Supervisory Board. ISA´s current Chairman Pieter van der Meijden will remain a member of the Supervisory Board.

Bart Bergstein has a strong track record in working with life sciences companies. He is a co-founder of Forbion Capital Partners, a leading European venture capital firm. At Forbion, he invested in numerous healthcare companies and served as a non-executive director on the board of many portfolio companies.

Leiden, The Netherlands, June 03, 2016 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the appointment of Bart Bergstein as Chairman of its Supervisory Board. ISA´s current Chairman Pieter van der Meijden will remain a member of the Supervisory Board.

Bart Bergstein has a strong track record in working with life sciences companies. He is a co-founder of Forbion Capital Partners, a leading European venture capital firm. At Forbion, he invested in numerous healthcare companies and served as a non-executive director on the board of many portfolio companies.

Interview with Prof. Cornelis Melief in the latest episode of the Novel Targets podcast:

https://soundcloud.com/noveltargets/episode-12-of-mice-and-men
http://noveltargets.com/2016/05/episode-12-of-mice-and-men/

Interview with Prof. Cornelis Melief in the latest episode of the Novel Targets podcast:

https://soundcloud.com/noveltargets/episode-12-of-mice-and-men
http://noveltargets.com/2016/05/episode-12-of-mice-and-men/

– Granted US patent provides market exclusivity until 2032

Leiden, The Netherlands, April 19, 2016 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced it has been granted a US patent on its AMPLIVANT® technology and compounds (patent no. 9,314,521). The patent ensures market protection in the United States until 2032 and covers the compounds, either as a stand-alone substance or in combination with antigenic peptides, nucleic acids or antibodies. The patent also covers the process for preparing the compounds.

ISA’s AMPLIVANT® technology provides an adjuvant that has been demonstrated